Biogen (BIIB) has agreed to pay $22 million to resolve allegations that donations it paid to charities were actually kickbacks to Medicare patients used to cover out-of-pockets costs for its multiple sclerosis medicines.

This is only the latest instance in which federal authorities have cracked down on such arrangements between drug makers and patient assistance charities. Over the past three years, some of the biggest names in the pharmaceutical industry – including Gilead Sciences (GILD), Pfizer (PFE), Amgen (AMGN), a Johnson & Johnson (JNJ) unit, Sanofi (SNY), and Novartis (NVS) – have reached similar agreements, as have several charities.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]